Liraglutide/insulin degludec

Liraglutide/insulin degludec is a combination medication used in the treatment of type 2 diabetes. It combines liraglutide, a GLP-1 receptor agonist, with insulin degludec, a long-acting insulin analog, to improve blood sugar control in adults with type 2 diabetes. This combination allows for the benefits of both medications, potentially reducing the number of injections needed and simplifying diabetes management.

Medical uses

Liraglutide/insulin degludec is indicated for the treatment of adults with type 2 diabetes mellitus when both liraglutide and insulin degludec are appropriate treatments. It is used alongside diet and exercise to improve glycemic control. Liraglutide works by increasing insulin secretion in response to high blood sugar levels, while insulin degludec provides a steady release of insulin to lower baseline blood sugar levels.

Administration

The medication is administered via subcutaneous injection. Patients should be instructed on proper injection techniques to minimize side effects and ensure effectiveness. The dosing of liraglutide/insulin degludec is individualized based on the patient's current treatment regimen, effectiveness, and tolerability.

Side effects

Common side effects include nausea, diarrhea, and headache. More serious side effects may include pancreatitis, hypoglycemia, and allergic reactions. Patients should be monitored for signs of pancreatitis and hypoglycemia and adjust their dosage as necessary.

Pharmacology

Liraglutide mimics the action of GLP-1, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, and slowing gastric emptying. Insulin degludec is designed to form a depot of insulin crystals in the subcutaneous tissue, from which small amounts of insulin are continuously released, providing a long duration of action.

Interactions

Liraglutide/insulin degludec may interact with other medications, including sulfonylureas and glucocorticoids, which can increase the risk of hypoglycemia. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

See also

• Diabetes management
• Insulin therapy
• GLP-1 receptor agonist

‎